Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy

Arthritis and Rheumatology

Volumn 66, Issue 2, 2014, Pages 444-450

  Cooper, William O ^a   Cheetham, T Craig ^b   Li, De Kun ^b   Stein, C Michael ^a   Callahan, S Todd ^a   Morgan, Thomas M ^a   Shintani, Ayumi K ^a   Chen, Ning ^a   Griffin, Marie R ^a   Ray, Wayne A ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CHRONIC DISEASE; CONGENITAL MALFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FETUS; FETUS DEATH; FETUS OUTCOME; FETUS RISK; HUMAN; IMMUNE MEDIATED DISEASE; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; NEWBORN DISEASE; OUTCOME ASSESSMENT; PERINATAL DRUG EXPOSURE; PREGNANCY; PREGNANCY DISORDER; PREGNANT WOMAN; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; YOUNG ADULT; ARTHRITIS; COHORT ANALYSIS; CONGENITAL DISORDER; DRUG ANTAGONISM; FOLLOW UP; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ARTHRITIS; COHORT STUDIES; CONGENITAL ABNORMALITIES; FEMALE; FETAL DEATH; FOLLOW-UP STUDIES; HUMANS; HYDROXYCHLOROQUINE; IMMUNE SYSTEM DISEASES; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; METHOTREXATE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896260999     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38262     Document Type: Article

References (15)

1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al, for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum 2008;58: 15-25.
2. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006;12: 6102-8.
3. Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. Am J Health Syst Pharm 2006;63: 2451-65.
4. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007;369: 587-96.
5. Beaulieu DB, Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol Clin North Am 2011;40:399-413, ix.
6. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30:24-9, 46.
7. Skomsvoll JF, Wallenius M, Koksvik HS, Rodevand E, Salvesen KA, Spigset O, et al. Drug insight: anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol 2007;3: 156-64.
8. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009;36: 635-41.
9. Li DK, Liu L, Odouli R. Exposure to non-steroidal antiinflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003;327:368.
10. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after firsttrimester exposure to ACE inhibitors. N Engl J Med 2006;354: 2443-51.
11. Centers for Disease Control and Prevention. Metropolitan Atlanta Congenital Defects Program coding manual. Atlanta: Centers for Disease Control and Prevention; 2011.
12. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159: 702-6.
13. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44: 1049-60.
14. MacDorman MF, Kirmeyer S. Fetal and perinatal mortality, United States, 2005. Natl Vital Stat Rep 2009;57: 1-19.
15. Milunsky A, Graef JW, Gaynor MF Jr. Methotrexate-induced congenital malformations. J Pediatr 1968;72: 790-5.